Evidence map›Paper›PMID 42719822›Full record

ArticleThe British journal of cardiology2026

GLP-1 receptor agonists in cardiovascular disease: a guide for cardiologists.

Sarah L Ayton, Dimitris Papamargaritis, Melanie J Davies, Gerry P McCann, Gaurav S Gulsin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarah L AytonClinical Research Fellow, Department of Cardiovascular Sciences and British Heart Foundation Centre of Research Excellence, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester.
Dimitris PapamargaritisAssociate Professor and Honorary Consultant in Diabetes and Endocrinology, Leicester Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester; Department of Diabetes and Endocrinology, Kettering General Hospital NHS Trust, Kettering.
Melanie J DaviesProfessor of Diabetes Medicine, Leicester Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester.
Gerry P McCannProfessor of Cardiac Imaging and Honorary Consultant Cardiologist, Department of Cardiovascular Sciences and British Heart Foundation Centre of Research Excellence, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester.
Gaurav S GulsinAcademic Clinical Lecturer, Department of Cardiovascular Sciences and British Heart Foundation Centre of Research Excellence, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a global epidemic, which, directly and indirectly, contributes to almost all cardiovascular diseases, including atherosclerotic cardiovascular disease, heart failure and atrial fibrillation. Reduction of weight is associated with substantial improvements in cardiometabolic risk factors, including blood pressure and glycaemic control, with over 10% weight loss required to see improvement in rates of major adverse cardiovascular events. Glucagon-like peptide-1 (GLP-1) receptor agonists have changed the landscape of type 2 diabetes and obesity management, showing significant benefit in glycaemic control and weight loss. Their potential for cardiovascular benefits means that they will likely have a central role in the management of patients with obesity-related cardiovascular diseases. This review summarises currently available GLP-1-based pharmacotherapies and highlights recent trials demonstrating cardiovascular benefits, and also provides practical guidance for patient selection, available agents, their initiation and patient monitoring. This will serve as an aid for cardiovascular clinicians, who will inevitably encounter patients suitable for, or already using, these drugs in their daily practice.

Indexed as

cardiovascular diseaseglucagon-like peptide-1 (GLP-1) receptor agonistsobesityweight loss

Identifiers

PMID42719822
PMCPMC13557138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.